HUE031633T2 - Fenotiazin-diaminium-sók és alkalmazásuk - Google Patents

Fenotiazin-diaminium-sók és alkalmazásuk Download PDF

Info

Publication number
HUE031633T2
HUE031633T2 HUE11749476A HUE11749476A HUE031633T2 HU E031633 T2 HUE031633 T2 HU E031633T2 HU E11749476 A HUE11749476 A HU E11749476A HU E11749476 A HUE11749476 A HU E11749476A HU E031633 T2 HUE031633 T2 HU E031633T2
Authority
HU
Hungary
Prior art keywords
compound
lmt
disease
acid
use according
Prior art date
Application number
HUE11749476A
Other languages
English (en)
Inventor
Colin Marshall
Scott Clunas
John Mervyn David Storey
James Peter Sinclair
Thomas Craven Baddeley
Ahtsham Ishaq
Michael Simpson
Craig Williamson
Barry Alan Wood
Claude Michel Wischik
Charles Robert Harrington
Janet Elizabeth Rickard
David Horsley
Yin Sze Loh
Karrar Ahmad Khan
Christopher Paul Larch
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of HUE031633T2 publication Critical patent/HUE031633T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029—Radiation
    • A61L2/0052—Visible light
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (15)

  1. , ALKALMAZÁSUK wmmtmmmMmimmöfc1 SzaMdatmt
    1. Vegyület, amelynek képlete:
    „ cMfoöadható sója, szolvátja vagy vagy ameiy annak gyogyszereszetileg *> hidrátja, enliser! vagy álla« »st terápiás «&** ^mvgéőzü kezelésire szolgáié eljárásban való alkalmazási a.
  2. 2. Vegyület alkalmazásra az 1. igénypont szerint, anieíy kristályos formában, van
  3. 3. Vegyület alkalmazásra az 1. vagy 2. igénypont szerint, amely lényegében véve tisztított formában van.
  4. 4. Vegyüíet alkalmazásra az t, vagy I- Igénypont szennf. amely olyan készítményben van jelen, amely taftáímazza a vegyüietet és gy&gyszerészefítsg elfogadható yivéinyagot vagy btgífponyagot,
  5. 6. Vegyület alkalmazásra a 4. igénypont szerint, ahoi a készítmény gyógyszerkészítmény, amely szilárd adagolás! forma, ameiy tartalmazza a vegyüietet és legalább egy olyan bigifószeri ameiy alkalmas száraz sajfoíásra. S. Vegyület alkalmazásra az 5. igénypont szerint, ahol a szilárd adagolási formát közvetlen sajtölássai vagy száraz granuiálással készítjük 11 Vegyület alkalmazásra az 5. vagy 8, igénypont szerint, ahoi az említett legalább egy hígítószert mikrokristályos cellulóz, faktóz, rnannlt, kalclumsok, így például dibázíkus kalcium-foszfát, kalcium-szulfát, kalcium-karbonát, és cukrok, így például laktóz, szacharóz, cíextroz és maftodextnn. Közül választjuk, I, Vegyület alkalmazásra az δ ~ 7. Igénypontok bármelyike szerint, ahol a készítmény tartalmaz további legalább agy szétesést elősegítő anyagot. i. Vegyület alkalmazásra a 8. igénypont szerint, ahoi a szétesést elősegítő anyagot térhiíósioi poííviniípírrolidon, náthüm-köményítő-glíkoiát, térhálósított ntfiirn-karb^i^tlNÂtôz vagy .©fózselatinált keményítő közül válaszfal:,
  6. 10, Vegyület alkalmazásra az 5 --9. igénypontok bármelyike szerint, ano! a szitám adagolási forma filmbevonatos. 11 Vegyület alkalmazásra az 5 - 10, igénypontok bármelyike szerint, ahol az említett készítmény tartalmaz továbbá olyan savat, amelynek pfCi értéke 1J-néí nagyobb.
  7. 12. Vegyület alkalmazásra:: a 11. igénypont szerint, ahol a savat maleinsav, foszforsav, aszkorbinsav. szorbinsav, aszparaginsav és sziáisav közül választjuk.
  8. 13. Vegyület alkalmazása a 11. vagy 12, igénypont; szerint, ahol az említett készítmény tartalmaz továbbá olyan vlvőanyagot. amelyet rnannit, ceiluíóztartalmú anyag, keményítő vagy ezek keverékei közül választunk. '14, Vegyület alkalmazásra az 5 - 13. igénypontok bármelyike szerint, azzal jeíiemézve, bogy a készítmény szemcséket tartalmaz, amelyeknek több. mint Í0!s~a 10 mikrométernél nagyobb méretű. iS, Vegyület 'alkalmazásra az1(^44- igénypontok bármelyike szerint:. amely ffiP-43 proteinop&tia kezelődére vagy megelőzésire szolgáló eljárásban való alkilmazásra szolgák
  9. 16, Vegyidet alkalmazásra az 1 ~~ 14. igénypontok bármelyike szerint amely taupátía kezelésére vagy megelőzésére szolgáíó eljárásban való alkalmazásra szolgál. W. Vegyöiet alkalmazásra az 1 ·· 14. igénypontok bármelyike szerint, amely Alzheímer-kór, Ptck-kor, progresszív szupranukleáris bénulás (PSP). frontoíemporálís demencia (FTÖ), a 17-es kromoszómához kaposöiedó FfD parkíneonizmuasál, frontotemporális lobárls degeneráció (FTLD} szindrómák, dlszínhibíció-dsmenbla-parkinsonizmus-arniotréla komplex, pajiidotoontm nigrális degeneráció, Duam-ÄS szindróma, palüdo-nigro-Luysian degeneráció, kortikóbazális degeneráció, argyrophil grain demeneia, demencia gugitisfea vagy krónikus traumáé enkefalopátia, Dovvmszindröma, hewyAesíes demencia, szubakut szklerotízáió pánenkeralltsz, enyhe kognitív zavar (MCI)., Niemaon#íck*ké| C-tipus, B-típusú Sanf iíippo-szindráma, DM1 y||y DM21 miotóniás dísztrófíák vagy amiotrófíás laterálszklerőzis (ALS) kezelésére vagy megelőzésére szolgáló eljárásban való alkalmazásra szolgál. 18, kegyelet alkalmazásra az 1 — 14. igénypontok bármelyike szerint, amely Alzheirner-kőr kezelésére vagy megelőzésére szolgáló eljárásban való alkalmazásra: szolgál. ti, Megyiiet álkaimazésra az 1 - 14. igénypontok bármelyike szerint, amely Parkínsomkór kezelésére vagy megelőzésére szolgáló eljárásban való alkalmazásra szolgál. 2Ő, Vegyület alkalmazásra az 1 - 14. igénypontok bármelyike szerint, amely PSP, ALS vagy FTLD kezelésére vagy megelőzésire szeifllő eljárásban való alkalmazásra szolgál
  10. 21, Veg^üíet alkalmazásra m 1 - 14. igénypontok bármelyike szerint, amely poiigíutamin-renéeiíenesség kezelésére vagy megelőzésére szolgáié eljárásban való alkalmazásra szolgái.
  11. 22. VegyDíet alkalmazásra a 21. igénypont szerint, amely Huntíngton-kór, spino-bafbirís Izom atrót'ía, éentato-rufem^palliáö-Luysian atrófia vagy spinoeereheüárís ataxiák kezelésére vagy megelőzésére szolgáié eljárásban való alkalmazásra szolgál.
  12. 23.,. Vegyület alkalmazásra az 1 - 14. igénypontok bármelyike szerint, amely bérrák vagy melanoma; vagy vírusos, bakteriális vagy protozoáé betegség állapot kezelésére vagy megelőzésére szolgáié eljárásban való alkalmazásra szolgál.
  13. 24, Vegyület alkalmazásra a 23. igénypont szerint, ábol a viruses, bakteriális vagy protozoáé betegség a kővetkezők közül való: Hepatitis C, HÍV, nyugat riílusi virus (VVNV'} és malária,
  14. 25. Vegyület alkalmazásra az 1 24. igénypontok bármelyike szerint, ahol a kezelés vagy megelőzés során a vegyuletet orálisan adagoljuk.
  15. 28, Vegyület alkalmazásra a 4 ~ 14. igénypontok bármelyike szerim, áfeot á készítmény tabletta vagy kapszula.
HUE11749476A 2011-02-11 2011-08-15 Fenotiazin-diaminium-sók és alkalmazásuk HUE031633T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG2011010600 2011-02-11
US201161485880P 2011-05-13 2011-05-13

Publications (1)

Publication Number Publication Date
HUE031633T2 true HUE031633T2 (hu) 2017-07-28

Family

ID=44532939

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11749476A HUE031633T2 (hu) 2011-02-11 2011-08-15 Fenotiazin-diaminium-sók és alkalmazásuk

Country Status (26)

Country Link
US (5) US9283230B2 (hu)
EP (1) EP2673266B1 (hu)
JP (2) JP5898701B2 (hu)
KR (1) KR101888713B1 (hu)
CN (2) CN105853439A (hu)
AR (2) AR082699A1 (hu)
AU (1) AU2011358840B2 (hu)
BR (1) BR112013020539A2 (hu)
CA (1) CA2827027C (hu)
CY (1) CY1118102T1 (hu)
DK (1) DK2673266T3 (hu)
EA (1) EA025033B1 (hu)
ES (1) ES2594703T3 (hu)
HK (1) HK1186738A1 (hu)
HR (1) HRP20161291T1 (hu)
HU (1) HUE031633T2 (hu)
IL (2) IL227736A (hu)
LT (1) LT2673266T (hu)
MY (1) MY165906A (hu)
PL (1) PL2673266T3 (hu)
PT (1) PT2673266T (hu)
RS (1) RS55237B1 (hu)
SG (1) SG192666A1 (hu)
SI (1) SI2673266T1 (hu)
SM (1) SMT201600389B (hu)
WO (1) WO2012107706A1 (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2013191B3 (en) 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
HUE030621T2 (hu) 2006-07-11 2017-05-29 Wista Lab Ltd Eljárások diaminofenotiazínium-vegyületek szintézisére és/vagy tisztítására
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
SG11201601003PA (en) * 2013-08-15 2016-03-30 Eupharma Pty Ltd Process for the purification of diaminophenothiazinium compounds
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015171592A1 (en) * 2014-05-06 2015-11-12 Milliken & Company Laundry care compositions
PL3283058T3 (pl) * 2015-04-16 2023-03-20 Novartis Ag Tabletka rybocyklibu
GB201512678D0 (en) * 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
CN106046027B (zh) * 2016-06-30 2019-03-05 广东工业大学 一种含吡咯并吩噻嗪-1,3-二酮衍生物及其制备方法与应用
EP4223297A3 (en) 2016-07-25 2023-11-15 WisTa Laboratories Ltd. Administration and dosage of diaminophenothiazines
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
MX2020000577A (es) 2017-07-20 2020-09-10 Aztherapies Inc Formulaciones en polvo de cromolina sodica e ibuprofeno.
JP6958860B2 (ja) 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
CN112955972A (zh) 2018-09-05 2021-06-11 云顶道卫思诊断中心有限公司 神经***变性疾病的网络方法
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
JP2023525512A (ja) 2020-05-05 2023-06-16 ウィスタ ラボラトリーズ リミテッド Ｃｏｖｉｄ－１９の治療で使用されるメチルチオニニウム化合物
GB202006659D0 (en) * 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
JP2023524146A (ja) 2020-05-05 2023-06-08 ウィスタ ラボラトリーズ リミテッド 低酸素血症の治療に使用されるメチルチオニニウム化合物
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
KR102396975B1 (ko) 2022-01-11 2022-05-12 이덕형 페이스 리프팅기 및 이를 위한 동작 방법
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment
WO2023202464A1 (zh) * 2022-04-19 2023-10-26 英科隆生物技术（杭州）有限公司 一种电子媒介体的提纯方法
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024063700A1 (en) 2022-09-21 2024-03-28 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (hu) 1957-07-17
US4309255A (en) 1980-09-10 1982-01-05 International Business Machines Corporation Electrochromic recording paper
US4647525A (en) 1984-10-01 1987-03-03 Minnesota Mining And Manufacturing Company Stabilized leuco phenazine dyes and their use in an imaging system
US4622395A (en) 1984-10-01 1986-11-11 Minnesota Mining And Manufacturing Company Phenoxazine and phenothiazine dyes and leuco forms thereof
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US4880373A (en) 1988-04-28 1989-11-14 The Upjohn Company Tablet press
US5571666A (en) 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
CA2011116C (en) 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
US5220009A (en) 1990-05-03 1993-06-15 Yeda Research And Development Company Limited Phenothiazinium salts and their use for disinfecting aqueous effluents
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
WO1993003177A1 (en) 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
DE4140192C2 (de) 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
ES2136654T3 (es) 1991-12-06 1999-12-01 Max Planck Gesellschaft Herramientas para el diagnostico y tratamiento de la enfermedad de alzheimer.
JPH06289015A (ja) 1993-03-30 1994-10-18 Sunstar Inc フェノチアジン系色源体安定化組成物
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
AU708682B2 (en) 1994-08-08 1999-08-12 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5693638A (en) 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
CA2278245A1 (en) 1997-01-21 1998-07-23 The American National Red Cross Intracellular and extracellular decontamination of whole blood and blood components by amphiphilic phenothiazin-5-ium dyes plus light
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
WO2001053340A2 (en) 2000-01-21 2001-07-26 Pharmacia & Upjohn Company Transgenic mouse model of human neurodegenerative disease
GB0017060D0 (en) 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
WO2003000714A2 (en) 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US7410965B2 (en) 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
US6953974B2 (en) 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
AU2004295148A1 (en) 2003-11-28 2005-06-16 Photopharmica Limited Developments in biologically active methylene blue derivatives (2)
CN101084204B (zh) 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
EP3564223A1 (en) 2004-09-23 2019-11-06 WisTa Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
WO2006091728A2 (en) 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
US20070116757A1 (en) 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
PT2004155T (pt) * 2006-03-29 2018-05-02 Wista Lab Ltd Inibidores de agregação proteica
EP2853293B1 (en) 2006-03-29 2017-11-22 WisTa Laboratories Ltd. Thioninium compounds and their use
EP2013191B3 (en) * 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
HUE030621T2 (hu) 2006-07-11 2017-05-29 Wista Lab Ltd Eljárások diaminofenotiazínium-vegyületek szintézisére és/vagy tisztítására
CN101820884B (zh) * 2007-06-19 2013-08-28 维斯塔实验室有限公司 用于治疗轻度认知缺损的吩噻嗪化合物
SI2205245T1 (sl) * 2007-10-03 2015-10-30 Wista Laboratories Ltd. Terapevtska uporaba diaminofenotiazinov

Also Published As

Publication number Publication date
KR101888713B1 (ko) 2018-08-14
IL249056B (en) 2019-09-26
DK2673266T3 (en) 2016-10-24
IL227736A0 (en) 2013-09-30
EP2673266A1 (en) 2013-12-18
CN103649061A (zh) 2014-03-19
AR082699A1 (es) 2012-12-26
US10864216B2 (en) 2020-12-15
HRP20161291T1 (hr) 2016-11-18
US9283230B2 (en) 2016-03-15
CN105853439A (zh) 2016-08-17
KR20140007428A (ko) 2014-01-17
PT2673266T (pt) 2016-10-07
US9907804B2 (en) 2018-03-06
ES2594703T3 (es) 2016-12-22
EA201391158A8 (ru) 2016-05-31
US20190046537A1 (en) 2019-02-14
JP6093890B2 (ja) 2017-03-08
JP5898701B2 (ja) 2016-04-13
EA201391158A1 (ru) 2014-02-28
IL249056A0 (en) 2017-01-31
US20130315992A1 (en) 2013-11-28
AU2011358840B2 (en) 2017-05-04
US20220098161A1 (en) 2022-03-31
US20160237048A1 (en) 2016-08-18
JP2014505095A (ja) 2014-02-27
CN103649061B (zh) 2016-04-20
SG192666A1 (en) 2013-09-30
CA2827027A1 (en) 2012-08-16
RS55237B1 (sr) 2017-02-28
US11180464B2 (en) 2021-11-23
AU2011358840A1 (en) 2013-09-12
JP2016138117A (ja) 2016-08-04
IL227736A (en) 2017-07-31
HK1186738A1 (zh) 2014-03-21
BR112013020539A2 (pt) 2017-09-26
EP2673266B1 (en) 2016-07-27
LT2673266T (lt) 2016-10-10
AR121016A2 (es) 2022-04-06
SI2673266T1 (sl) 2016-11-30
EA025033B1 (ru) 2016-11-30
WO2012107706A1 (en) 2012-08-16
CA2827027C (en) 2019-06-04
PL2673266T3 (pl) 2017-01-31
CY1118102T1 (el) 2017-06-28
US20200246350A1 (en) 2020-08-06
MY165906A (en) 2018-05-18
WO2012107706A8 (en) 2013-09-19
SMT201600389B (it) 2017-01-10

Similar Documents

Publication Publication Date Title
US11180464B2 (en) Phenothiazine diaminium salts and their use
JP5814957B2 (ja) ３，７−ジアミノ−１０ｈ−フェノチアジン塩およびその使用
JP6735810B2 (ja) 置換１０ｈ−フェノチアジン−３，７−ジアミン化合物の化学合成方法
WO2024061971A1 (en) Novel formulations and vehicles